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Abstract
Bone morphogenetic protein-2 (BMP-2)-containing bone grafts are useful regenerative materials for oral and maxillofacial
surgery; however, several in vitro and in vivo studies previously reported cancer progression-related adverse effects caused
by BMP-2. In this study, by quantifying the rhBMP-2 content released from bone grafts, the rhBMP-2 concentration that did
not show cytotoxicity in each cell line was determined and applied to the in vitro monoculture or coculture model in the
invasion assay. Our results showed that 1 ng/ml rhBMP-2, while not affecting cancer cell viability, significantly increased the
invasion ability of the cancer cells cocultured with fibroblasts. Cocultured medium with rhBMP-2 also contained increased
levels of matrix metalloproteinases. rhBMP-2-treated cocultured fibroblasts did not show a prominent difference in mRNA
expression profile. Some cytokines, however, were detected in the conditioned medium by a human cytokine antibody
array. Among them, the cancer invasion-related factor CCL5 was quantified by ELISA. Interestingly, CCL5 neutralizing
antibodies significantly reduced the invasion of oral cancer cells. In conclusion, our results suggest that 1 ng/ml rhBMP-2
may induce invasion of oral squamous cell carcinoma (OSCC) cells by CCL5 release in coculture models. Therefore, we
propose that a careful clinical examination before the use of rhBMP-2-containing biomaterials is indispensable for using
rhBMP-2 treatment to prevent cancer progression.
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Introduction
Oral cancer is the sixth most common malignancy worldwide
and is occurring with increasing frequency [1]. The best known
risk factors of this multifactorial disease include tobacco, alcohol,
betel quid chewing, genetic predisposition, the presence of
potentially malignant lesions, etc. [2,3]. Inflammation caused by
exogenous materials is also known to be associated with cancer
initiation and development. Some biomaterials used for the
recovery of human body during surgery and healing processes
were shown to be irritants or oncogenes. Especially, in dentistry, it
is known that dental implants for hard tissue reconstruction can be
causative agents of unexpected side effects including oral cancer in
some cases [4–6].
Currently, bone morphogenetic protein-2 (BMP-2) has become
a popular commercial drug used for hard tissue regeneration in
orthopedic surgery and dental treatment in the form of bone graft
coating, membranes, or solutions. BMPs are originally identified as
osteogenic cytokines that promote bone and cartilage formation
in vivo [7,8]. BMPs regulate developmental epithelial-to-mesen-
chymal transition, including neural crest migration and cardiac
morphogenesis [9]. However, BMP-2 overexpression has been
demonstrated to result in changes in cell morphology and
increased cell motility and invasiveness in the pancreatic, gastric,
prostate and breast cancer cells [10–14]. Moreover, a recent
report published by the Food and Drug Administration described
BMP-2-induced adverse effects such as bone resorption, local
inflammation, ectopic bone formation, and cancer; specifically, 86
reports of oral and maxillofacial surgery from 2002 to 2011 were
found to display negative outcomes [15]. Therefore, it is inevitable
to establish methods that could accurately evaluate whether BMP-
2 exogenously injected for oral hard tissue regeneration is
associated with oral cancer.
The relationship between cancer cells and BMP-2 has been
investigated in several studies. During clinical research, spinal
surgery with high-dose rhBMP-2 treatment led to four-fold
increase in the number of new malignancies after 24 months,
compared to the untreated group, and the discrepancy increased
after 60 months [16]. Studies analyzing 25 tongue squamous cell
carcinomas by gene microarray and qPCR analyses revealed that
BMP-2 gene expression may be associated with lymph node
metastasis [17]. In addition, ectopic expression of BMP-2
stimulated angiogenesis in developing tumors and resulted in
significantly increased local invasion and metastasis in melanoma
[18,19], lung cancer cells [20,21], and breast cancer cells [22].
However, findings of these previous studies are insufficient for
revealing the role of BMP-2 and its mechanism related to oral
cancer progression.
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The effect of fibroblasts on oral cancer progression related to
BMP-2 has not yet been considered, although stromal fibroblasts
are known as important and main host cell types in tumor
microenvironments. Cancer-associated fibroblasts are responsible
for the production of paracrine growth factors, proteolytic
enzymes, and extracellular matrix (ECM) components, through
which the combination of epithelial cancer cells and fibroblasts
promote tumorigenesis and development of tumors that are larger
than malignant epithelia alone [23]. Based on these findings,
investigators should consider a combined evaluation system with
regard to cancer cells and nearby stroma, especially fibroblasts,
and design in vitro experimental models that could reflect these
in vivo environments. For this experimental design, there were
some invasion assays in the previous studies [24–26], but more
natural methods that enable an easy analysis and quantification of
OSCC invasion in vitro should be used for accurate evaluations of
cancer progression.
Biological reactions in response to various irritants are different,
depending on the general conditions and local status of hosts.
Therefore, in this study, we assumed the situation that clinicians
would not detect or disregard the signs of pre-existing oral cancer
cells before BMP-2 treatment for bone-defective areas. Consider-
ing this clinical situation, we developed an in vitro system that
combined BMP-2 and pre-existing oral cancer cells with or
without fibroblasts. With the use of cancer cells either mono-
cultured or cocultured with fibroblasts in vitro, we studied the
effects of BMP-2 on the invasion ability of oral squamous cell
carcinoma (OSCC) cell lines and analyzed the transformation and
releasing factors of these cells. Our results suggest that detection of
premalignant signs is important prior to BMP-2 treatment and
that clinicians should recognize the possible danger of BMP-2
depending on patients’ oral conditions. Furthermore, this evalu-
ation method for regenerative materials or drugs would be useful
in the development and approval process.
Materials and Methods
Quantification of BMP-2 extracted from bone graft
materials by ELISA
Each bone graft material (2 g) described in Table S1 was
incubated with 2 ml of complete protease inhibitor cocktail
(Roche, Mannheim, Germany) at 4uC for 4 weeks. After
extraction, samples were centrifuged at 12,000 rpm for 10 min,
and the supernatants were analyzed using the BMP-2 ELISA Kit
(R&D Systems, Minneapolis, MN, USA) [28,29]. This experiment
was repeated independently three times under the same condi-
tions.
Preparation of OSCC cell lines, immortalized fibroblasts,
and rhBMP-2
Two OSCC cell lines, namely, YD-10B and YD-38 (origin,
human tongue and human lower gingiva, respectively), were
obtained from the Korean Cell Line Bank (Seoul, Korea) and
cultured as described previously before [30]. HSC-2 cells (origin,
human tongue), a gift from Prof. Takashi Muramatsu, Tokyo
Dental College, Japan, were maintained in DMEM: Ham’s F12
(3:1; Gibco, NY, USA), supplemented with 10% FBS and 1%
penicillin/streptomycin. Human immortalized fibroblasts
(hTERT-hNOF), which were established previously [31], were
cultured either alone or with OSCC cell lines. rhBMP-2 was
purchased from the Korea Bone Bank (Seoul, Korea) and diluted
in cell culture medium to various concentrations.
Cell viability assay
Three OSCC cell lines (YD-10B, YD-38, and HSC-2) and
fibroblasts (26104 cells/well) were seeded on 24-well culture plates
and cultured for 24 h. Next, cells were treated with rhBMP-2 (0, 1,
5, 10, 20, and 40 ng/ml) in serum-free medium for 24, 48, or 72 h
under 5% CO2. The rhBMP-2 non-treated group was used as a
control. The cell viability assay was performed using WST
Solution (Daeil Lab, Seoul, Korea) according to the manufactur-
er’s instructions, and the absorbance was measured at 450 nm by
an Epoch spectrophotometer (BioTek, VT, USA). The cell
viability of each experimental group was expressed as the
percentage of the cell viability of the control. Three independent
experiments were performed under identical conditions.
Invasion assay
To evaluate the invasive activity of cancer cells, a modified
transwell invasion assay was carried out as described previously
[32]. Briefly, 24-well transwell plates (Corning, NY, USA), along
with inserts containing 8-mm pore size filters coated with collagen
type I (30 ml/well), were used. Fibroblasts (26104 cells/well) were
placed in the lower wells of chambers with 10% FBS and 1%
antibiotics. After their attachment for 24 h, media for fibroblasts
was replaced with serum-free one containing rhBMP-2 (1 ng/ml).
And each OSCC line (26104 cells/transwell) was seeded in the
upper part (porous filter with collagen layer). OSCC monocultures
were obtained by culturing OSCC cell lines without fibroblasts on
the same side of filters. The rhBMP-2 non-treated group was used
as a control. This condition was maintained for 48 h. OSCC cells
penetrating though filters were fixed with formaldehyde (Sigma-
Aldrich, MO, USA), stained with hematoxylin solution (Sigma-
Aldrich), and counted under a light microscope. Experiments were
repeated three times under identical conditions.
Microarray analysis
OSCC cells (YD-38 or HSC-2) and fibroblasts (1.76105) were
seeded in upper and lower chambers, respectively, of 6-well
transwell plates containing collagen-coated transmembrane filters
(pore size, 1 mm) (Becton, Dickinson and Company, Franklin
Lakes, NJ). After cells were incubated either with or without
rhBMP-2 (1 ng/ml) in serum-free medium for 48 h, total RNA
was isolated from underlying fibroblasts by using Trizol Reagent
(Invitrogen, Carlsbad, CA) and subjected to microarray analysis,
as described in the Methods S1.
Human matrix metalloproteinase (MMP) antibody array
Cell supernatants were obtained from the cocultures of YD-38
and fibroblasts or monocultured fibroblasts treated with or without
rhBMP-2 (1 ng/ml) for 48 h and subjected to the human MMP
antibody array (Ray Biotech, GA, USA). The relative expression
levels of released MMPs and tissue inhibitors of metalloproteinases
(TIMPs) were calculated by comparing their levels before and after
rhBMP-2 treatment.
Measurement of secreted cytokines by the human
cytokine antibody assay and ELISA
YD-38 cells cocultured with fibroblasts in 24-well transwell
plates were treated with or without rhBMP-2 (1 ng/ml) for 48 h,
and the supernatants were then subjected to the human cytokine
antibody array (Ray Biotech, GA, USA). The relative expression
level of cytokines was determined by comparing signal intensities.
Monoculture supernatants were obtained by culturing OSCC
cell lines or fibroblasts on the same side of filters as described in the
coculture design. Cells were cultured for 48 h with either 1 ng/ml
BMP-2-Induced Cancer Progression
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rhBMP-2-containing medium or pure serum-free medium. The
CCL5 levels in supernatants obtained from monoculture or
coculture models were quantified using the Human CCL5 ELISA
Kit (R&D Systems, MN, USA). Experiments were performed
three times under identical conditions.
Treatment of coculture models with CCL5 neutralizing
antibodies and rhBMP-2 and invasion assay
CCL5 neutralizing antibodies (R&D Systems, MN, USA), along
with rhBMP-2, were added to coculture models in 24-well
transwell plates coated with collagen type I (50 ml/well) for 48 h.
Control group was set as the one with rhBMP-2 (1 ng/ml) and
IgG antibody. Three treatment groups were as follows: control,
rhBMP-2 (1 ng/ml) plus CCL5 neutralizing antibody (0.01 mg/
ml), and rhBMP-2 (1 ng/ml) plus CCL5 neutralizing antibody
(0.05 mg/ml). Finally, invading cells were fixed, stained, and
counted as described before.
Statistical analysis
Statistical comparisons were performed by the two-sample t test.
Data were given as means 6 standard deviations in graphs.
Significance was established when P,0.05.
Results
BMP-2 content in bone graft materials
As shown in Table S1, the synthetic rhBMP-2-coated product
BMP (Cowellmedi, Korea) released the highest amount of BMP-2.
The BMP-2 content in the allografts, xenografts, and synthetic
grafts varied and did not depend on the type of bone grafts. The
average concentration of rhBMP-2 extracted from all graft
materials was 1047 pg/ml.
rhBMP-2 (1 ng/ml) has no significant effect on the cell
viability of three OSCC cell lines and fibroblasts
While the cell viability of three OSCC cell lines and fibroblasts
was decreased by rhBMP-2 in a concentration-dependent manner
(0–40 ng/ml; Fig. 1), 1 ng/ml rhBMP-2 did not reduce cell
viability, except in case of YD-10B that were treated for 72 h.
Notably, in contrast to YD-10B and fibroblasts, the viability of
YD-38 and HSC-2 cells increased at all concentrations after 48
and 72 h of treatment. Since 1 ng/ml rhBMP-2 had no significant
effects on the cell viability of three OSCC cell lines and fibroblasts
after 24 and 72 h h and the average rhBMP-2 concentration
extracted from graft materials was 1047 pg/ml, rhBMP-2 at the
concentration of 1 ng/ml was used in subsequent experiments.
rhBMP-2 promotes cell invasion of three OSCC cell lines
The schematic diagram of the invasion assay is shown in
Fig. 2a. Monocultured OSCC cell lines did not invade through
collagen membranes, regardless of rhBMP-2 treatment (Fig. 2h,
all mean values were lower than 10). In contrast, YD-10B, YD-38,
and HSC-2 cocultured with fibroblasts invaded to the bottom
surface of collagen-coated transwell plates at significantly higher
levels without FBS (Fig. 2h). Especially, upon rhBMP-2 treatment,
cocultured YD-38 proliferated into clusters and showed the
highest number of invading cells among all groups (mean; 466)
(Fig. 2d vs. 2e).
rhBMP-2 causes little genetic changes in cocultured
fibroblasts
The fibroblasts cocultured with YD-38 or HSC-2 were treated
with 1 ng/ml rhBMP-2, and genome-wide gene expression
profiles of the fibroblasts were then analyzed by the microarray
analysis. Significant genetic changes were only detected in the
FAM21A gene (fold change, ,2.2; P,0.05; Table S2). Alterations
with over 1.5-fold changes were also summarized in Table S2.
rhBMP-2 increases MMP release in coculture models
The release of MMPs from monocultured fibroblasts was found
to be decreased by treatment with 1 ng/ml rhBMP-2 when
compared with the non-treated control (Fig. S1). However, the
coculture supernatant of YD-38 and fibroblasts showed increased
levels of all MMPs, especially MMP-10, MMP-13, and TIMP-1,
after rhBMP-2 treatment, compared to the non-treated control
(Fig. 3a–c).
Treatment of cocultured OSCC models with rhBMP-2
significantly increases CCL5 release
The human cytokine array analysis indicates that the fibroblasts
cocultured with YD-38 and treated with 1 ng/ml rhBMP-2
showed decreases in the release of most cytokines, except CCL5,
CXCL12, CCL17, VEGF, and PDGF (Fig. 3f). The level of
CCL5, in particular, was markedly increased in intensity from 230
to 337 (Fig. 3d–f, in the red box). Since CCL5 was previously
shown to be a representative protein related to cancer invasion
[33–36], we considered that CCL5 may be a key factor in oral
cancer invasion upon rhBMP-2 treatment.
The release of human CCL5 proteins was further validated by
ELISA (Fig. 4). In the coculture groups (YD10B-F, YD38-F, and
HSC2-F), treatment with 1 ng/ml rhBMP-2 resulted in significant
increase in CCL5 release (P,0.05); in contrast, monocultured
OSCC cell lines or fibroblasts showed either reduced or
unchanged levels of CCL5 release after rhBMP-2 treatment.
CCL5 neutralizing antibodies inhibit OSCC cell invasion
induced by rhBMP-2
As shown in Fig. 2, rhBMP-2 (1 ng/ml) treatment led to
significant increases in cell invasion of three OSCC cell lines;
however, the number of OSCC cells penetrating through 50 ml of
collagen type I were less than those penetrating through 30 ml of
collagen (Fig. 5). As shown in Fig. 5g, 0.01 mg/ml of CCL5
neutralizing antibodies reduced the amount of invading cells in
every group, compared to the control (YD-10B; 73 to 69, YD-38;
243 to 153, HSC-2; 162 to 116). In particular, in YD-10B and
YD-38 cells, the effect of CCL5 neutralizing antibodies was
notably greater at the concentration of 0.05 mg/ml than at
0.01 mg/ml.
Discussion
Multiple microenvironmental alterations occur during cancer
progression; these changes include increased numbers of fibro-
blasts, blood vessels, immune cells, and ECM components. The
crosstalk between normal fibroblasts and cancer-associated fibro-
blasts and epithelial cells is also known to contribute to cancer
progression. Thus, there are modifications of normal fibroblasts to
cancer fibroblasts and remodeling of ECM by degradation and
increased stiffness. The coculture condition used in this study has
an advantage for evaluating cell-to-cell interactions in cancer
microenvironments, as well as the contribution of stromal
fibroblasts to cancer cells. We believe that such an in vitro model
(cocultures of OSCC cell lines and fibroblasts) mimics the in vivo
system and can therefore be a critical and powerful tool. In a
previous study, cocultures of breast carcinoma cell lines with
fibroblastic stromal cells resulted in marked induction of aroma-
tase enzymatic activity and mRNA expression [37], both of which
BMP-2-Induced Cancer Progression
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Figure 1. Cell viability of three OSCC cell lines and fibroblasts. Data are expressed as the percentage of respective non-treated control
groups. Data shown are means of three independent repeats, and error bars indicate standard deviation. *P,0.05 compared to the negative control.
doi:10.1371/journal.pone.0108170.g001
Figure 2. Invasion assay in monoculture or coculture models. (a) Schematic diagram of the invasion assay and cellular changes. Carcinoma
cells on the transwell penetrate the collagen membrane when cocultured with fibroblasts and then finally attach to the lower surface of the transwell.
(b–g) Cocultured YD-10B (b and c), YD-38 (d and e), and HSC-2 (f and g) cells either untreated (b, d, and f) or treated with 1 ng/ml rhBMP-2 (c, e, and
g). (h) Quantification of the invasion ability of OSCC cells. Data shown are means of three independent repeats, and error bars indicate standard
deviation. *P,0.05 compared to the control.
doi:10.1371/journal.pone.0108170.g002
BMP-2-Induced Cancer Progression
PLOS ONE | www.plosone.org 4 October 2014 | Volume 9 | Issue 10 | e108170
are generally below the detection level partly due to the lack of
interactions between parenchymal or carcinoma cells and stromal
cells. Therefore, in this report, we evaluated the effects of rhBMP-
2 on cancer cells in coculture models. Our results show that while
monocultured cancer cells did not exhibit any cell invasion ability,
all cocultured ones showed increased invasion rates (Fig. 2h).
rhBMP-2 exerted inhibitory effects on the growth of OSCC cell
lines and fibroblasts and these effects became more evident as the
rhBMP-2 concentration was increased from 0 to 40 ng/ml, as
shown in Fig. 1. These results are in agreement with those of
previous studies on the effects of rhBMP-2 on HUVEC cells,
breast tumor cells, gastric mucosal cells, and gastric cancer cells
[38–40]. Specifically, BMP-2 was shown to not only cause G1
arrest of monocultured cancer cells but also reduce the number of
cells in S phase and their CDK4 expression [39]. This study also
proved that rhBMP-2 exerted similar effects on the OSCC cell
lines and fibroblasts. Importantly, rhBMP-2 at the concentration
of 1 ng/ml, which is approximately the average content of
rhBMP-2 released from bone graft materials (Table S1), did not
affect the cell viability (Fig. 1). Therefore, 1 ng/ml was considered
to be an appropriate concentration used to evaluate the effects of
rhBMP-2 on cancer cells in subsequent experiments, although the
content of BMP-2 obtained from bone graft materials depends on
the extraction method and time and dilution ratios.
As shown in Fig. 2 and 5, 1 ng/ml rhBMP-2-treated coculture
models increased cancer cell invasion through 30 or 50 ml of
collagen membranes. In a previous study, BMP2 increased the
invasion ability of OSCC cell lines (demonstrating gene expression
of BMP2) and this effect enlarged when BMP2 combined with
FBS was treated to the cells. OSCC cell lines cocultured with
fibroblasts can release chemokines and cytokines to the media and
invade through transwell without FBS [41]. It was known that
Figure 3. MMP and cytokine antibody array for cocultured YD-38 and fibroblasts. (a–c) MMP array for cocultured YD-38 cells either
untreated (a) or treated with rhBMP-2 (b). (c) Quantification of the levels of various MMPs. (d–f) Cytokine array of cocultured YD-38 cells either
untreated (d) or treated with rhBMP-2 (e). (f) Quantification of the levels of various cytokines. Red boxes in (d) and (e) show the changes of signal
intensities of CCL5 before and after 1 ng/ml rhBMP-2 treatment, respectively, which were quantified and compared in the red box of (f).
doi:10.1371/journal.pone.0108170.g003
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cancer cell-derived TGF-b1 was responsible for inducing trans-
differentiation of oral normal fibroblasts into cancer associated
fibroblasts (CAF)-like cells and CAF-like cells secret high levels of
growth factors that enhance OSCC cell line invasion and
proliferation [42]. Therefore, the existence of fibroblasts and its
stimulation have a key role in increased invasion ability of OSCC
cell lines by rhBMP-2 in this study.
Increased OSCC cell invasion occurred concurrently with the
increased levels of matrix metalloproteinases (MMPs) and their
endogenous inhibitors, namely, tissue inhibitors of metalloprotei-
nase (TIMPs). It was already known that increased expression of
certain MMPs plays a significant role in ECM degradation,
disrupts cell-cell contact through E-cadherin [43], and therefore
correlates with tumor invasion [44]. Among the upregulated
MMPs shown in Fig. 3, MMP-10 has been suggested to play an
important role in the invasion and metastasis of head and neck
cancer [45], and MMP-13 is known as a commonly upregulated
gene by cancer invasion-related factors, thereby promoting tumor
angiogenesis [46]. TIMP-1 is frequently overexpressed in several
types of human cancers and serves as a prognostic marker [47,48].
Taken together, our data support that rhBMP-2 increases the
invasion ability of cancer cells.
CCL5 level increased markedly after the treatment of 1 ng/ml
rhBMP-2 in the YD-38 coculture model. Since this cytokine has
been previously suggested to be a factor related to cancer cell
invasion, we next investigated the role of CCL5 in the cancer cell
invasion assay. In Fig. 5, YD-10B, YD-38, and HSC-2 coculture
models that were treated with both rhBMP-2 and CCL5
antibodies had less invading cells, compared to those treated with
rhBMP-2 alone (P,0.05), and that the inhibitory effects were
dependent on the concentration of the neutralizing antibodies.
These data clearly suggest that interfering with CCL5 signaling by
using specific neutralizing antibodies may be an attractive
approach to offer protection against OSCC cell invasion. The
Figure 4. Human CCL5 ELISA of monocultured or cocultured medium with or without 1 ng/ml rhBMP-2. Data shown are means of three
independent repeats, and error bars indicate standard deviation. *P,0.05 compared to the control.
doi:10.1371/journal.pone.0108170.g004
Figure 5. Invasion assay of coculture models treated with rhBMP-2 and CCL5 neutralizing antibodies. (a–f) Representative invasion
results of YD-10B (a and b), YD-38 (c and d), and HSC-2 (e and f) cocultured cells treated with either 1 ng/ml rhBMP-2 only (a, c, and e) or both rhBMP-
2 and 0.05 mg/ml CCL5 neutralizing antibodies (b, d, and f). (g) Quantification of the invasion ability of OSCC cell lines. Data shown are means of three
independent repeats, and error bars indicate standard deviation. *P,0.05 compared to the control.
doi:10.1371/journal.pone.0108170.g005
BMP-2-Induced Cancer Progression
PLOS ONE | www.plosone.org 6 October 2014 | Volume 9 | Issue 10 | e108170
investigation by Salo S et al. also showed such results in human
squamous cell carcinoma originated from tongue, in which CCL5
function-blocking monoclonal antibody inhibited the invasion
bone marrow-derived multipotent mesenchymal stromal cells
(BMMSCs)-promoted HSC-3 cell invasion area [27]. Similar
results have also been shown in colorectal cancer, breast cancer,
and prostate cancer [49–51]. However, noticeably, interfering
with CCL5 signaling did not completely inhibit rhBMP-2-induced
cell invasion, implicating the involvement of other pathways. For
instance, CXCL9 [51], CXCL12 [52], PDGF-BB [53], and
VEGF [54], all of which are well-known factors associated with
cancer cell invasion, were also detected by the cytokine antibody
array in this study. Future studies will be necessary to determine
whether combined blockage of these proteins will provide
protection against BMP-2-induced oral cancer progression.
Based on the invasion assay, the cocultured OSCC cell lines
treated with rhBMP-2 were found to exhibit more invasive
characteristics in vitro than the monocultured ones. However, the
fibroblasts cocultured with YD-38 or HSC-2 demonstrated no
common genetic alterations with over 2-fold changes. Although
one common gene, RN7SK, was found to be downregulated (fold
change, ,1.5) in Table S2, its expression was comparatively weak.
A better understanding of the relationship of RN7SK with
cytokines and cancer cell invasion will be necessary for elucidating
its correlation with rhBMP-2 and cancer invasion.
Despite these limitations, our study discusses the probability of
unconsidered adverse effects caused by 1 ng/ml rhBMP-2 and
warns rhBMP-2-induced invasion and progression of pre-existing
cancer cells that might not be detected in a diagnostic process. In
addition, this study also emphasizes the importance of the in vitro
coculture system (cancer cells with fibroblasts) for the evaluation of
cancer progression induced by regenerative biomaterials. Howev-
er, it is too early to conclude that rhBMP-2 is a carcinogenic
material at specific concentrations because many previous studies
evaluated the effects of rhBMP-2 in vivo. Therefore, generation of
an appropriate animal model for the application of rhBMP-2 is
additionally necessary in a further study. In conclusion, consid-
ering the chances of negative effects with oral usage of rhBMP-2,
close examination and thorough diagnosis of cancers are
indispensable before the use of rhBMP-2. Additionally, malignant
tissues near the defective areas should be treated or removed in
advance to eliminate the possibility of adverse effects caused by
rhBMP-2.
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